You are here: Industry Insights > CD47

News List

I-Mab to Present Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma at ASH 2021 prnasia
November 05, 2021
I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that an abstract...
CD47 Monoclonal Antibody (AK117) Completed Phase I Dose Escalation Trial and Obtained Approval to Initiate Clinical Trial in Combination with Azacitidine for Treatment of Acute Myeloid Leukemia prnasia
July 13, 2021
Akeso, Inc. is pleased to announce that, CD47 monoclonal antibody (AK117), a second-generation novel drug for immuno-oncology therapy independently developed by the Company, has completed phase I dose escalation trial in Australia.
Trillium Therapeutics Joins Russell 2000 and 3000 Indices firstwordpharma
June 28, 2021
Trillium Therapeutics Inc. joins the broad-market Russell 2000® and 3000® Indices effective after the US market opens on June 28.
Innovent Announces First Patient Outside China Dosed in the Phase 1 Clinical Trial of Anti-CD47/PD-L1 Bispecific Antibody prnasia
March 01, 2021
Innovent Biologics, Inc. announces that the first patient outside China has been successfully dosed in a Phase 1 clinical trial of the potentially first-in-class recombinant anti-CD47/PD-L1 bispecific antibody (IBI322).
I-Mab Accelerates Clinical Development of Anti-CD47 Monoclonal Antibody Lemzoparlimab in the US and China prnasia
December 07, 2020
I-Mab announced the advancement of clinical development of the highly differentiated anti-CD47 monoclonal antibody lemzoparlimab (also known as TJC4) in the US and China, achieving milestones as planned.
Innovent Releases Phase 1a Results of CD47 Monoclonal Antibody (Letaplimab) in Monotherapy for Advanced Malignancies at SITC 2020 prnasia
November 11, 2020
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces that the results of the ...
I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting prnasia
November 10, 2020
I-Mab announced initial results from its U.S. phase 1 clinical trial (NCT03934814) evaluating lemzoparlimab (also known as TJC4) for the treatment of relapsed or refractory solid tumors and lymphoma.
Gut bacteria can penetrate tumors and aid cancer therapy worldpharmanews
March 10, 2020
Researchers at the University of Texas Southwestern Medical Center and University of Chicago have discovered that bacteria that usually live in the gut can accumulate in tumors and improve the effectiveness of immunotherapy in mice.
I-Mab Announces Dosing of First Patient in a Phase I Clinical Trial of TJC4 americanpharmaceuticalreview
June 26, 2019
I-Mab Biopharma announced the first patient has been dosed in a Phase I clinical trial of TJC4. The study is known as TJ011133 (NCT Number: NCT03934814).
Big Secret Uncovering! Hengrui’s SHR-1603 just Approved for Clinical Trial is Next Anti-CD47 Star in the Tumor Immunotherapy Field! Caicai
August 03, 2018
Hengrui announced at the end of last month that it had received the Drug Clinical Trial Approval issued by the State Drug Administration of China (SDA) and would conduct Phase I clinical trial soon.

Previous page 1 2 Next page